CohBar to Present at the H.C. Wainwright Global Investment Conference
May 19 2022 - 4:02PM
CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company
leveraging the power of the mitochondria and the peptides encoded
in its genome to develop potential breakthrough therapeutics
targeting chronic and age-related diseases, announced today its
virtual participation in the 2022 H.C. Wainwright Global
Investment Conference.
Dr. Joseph Sarret, CohBar’s Chief Executive Officer,
will present a company overview available for on-demand
listening starting Tuesday, May 24, 2022, at 7:00 a.m.
Eastern Time. Interested parties can register for the
conference and view the presentation
here: www.hcwevents.com/globalconference.
The presentation can also be accessed on the Events &
Presentations page of the Investors section of CohBar’s website
at https://www.cohbar.com/investors/news-events. An archived
replay of the webcast will be available on CohBar’s website for at
least 30 days after the event concludes.
About CohBar
CohBar (NASDAQ: CWBR) is a clinical-stage
biotechnology company leveraging the power of the mitochondria and
the peptides encoded in its genome to develop potential
breakthrough therapeutics targeting chronic and age-related
diseases with limited to no treatment options. CohBar has assembled
the leading position in exploring the mitochondrial genome and its
utility for the development of novel therapeutics, including
world-renowned expertise in mitochondrial biology, a broad
intellectual property estate, key opinion leaders and disciplined
drug discovery and development processes. CohBar is utilizing its
Mito+ platform to identify and develop modified versions of natural
peptides called analogs to treat a variety of serious conditions,
with a focus on diseases involving inflammation and fibrosis.
For additional company information, please visit www.cohbar.com
and engage with us on LinkedIn.
Forward-Looking Statements
This news release contains forward-looking statements that are
not historical facts within the meaning of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements are based
only on our current beliefs, expectations and assumptions regarding
the future of our business, future plans and strategies,
projections, anticipated events and other future conditions. In
some cases you can identify these statements by forward-looking
words such as “believe,” “may,” “will,” “estimate,” “continue,”
“anticipate,” “intend,” “could,” “should,” “would,” “project,”
“plan,” “expect,” “goal,” “seek,” “future,” “likely” or the
negative or plural of these words or similar expressions. Examples
of such forward-looking statements include but are not limited to
statements regarding ongoing and planned research and development
activities; expectations regarding the growth of therapies
developed from modified mitochondrial peptides as a significant
future class of drug products; and statements regarding anticipated
therapeutic properties and potential of our mitochondrial peptide
analogs and other potential therapies. You are cautioned that such
statements are not guarantees of future performance and that actual
results or developments may differ materially from those set forth
in these forward-looking statements. Factors that could cause
actual results to differ materially from these forward-looking
statements include: our ability to successfully advance drug
discovery and development programs, including the delay or
termination of ongoing clinical trials and the timing of
announcements and updates relating to our clinical trials and
related data; our possible inability to mitigate the prevalence
and/or persistence of the injection site reactions, or the
possibility of other developments affecting the viability of CB4211
or CB5138-3 as a clinical candidate or its commercial potential;
results that are different from earlier data results including less
favorable results that may not support further clinical
development; our ability to raise additional capital when necessary
to continue our operations; our ability to recruit and retain key
management and scientific personnel; the risk that our intellectual
property may not be adequately protected; our ability to establish
and maintain partnerships with corporate and industry partners; and
risks related to the impact on our business of the COVID-19
pandemic or similar public health crises. Additional assumptions,
risks and uncertainties are described in detail in our registration
statements, reports and other filings with the Securities and
Exchange Commission and applicable Canadian securities regulators,
which are available on our website, and
at www.sec.gov or www.sedar.com.
You are cautioned that such statements are not guarantees of
future performance and that our actual results may differ
materially from those set forth in the forward-looking statements.
The forward-looking statements and other information contained in
this news release are made as of the date hereof and CohBar does
not undertake any obligation to update publicly or revise any
forward-looking statements or information, whether as a result of
new information, future events or otherwise, unless so required by
applicable securities laws. Nothing herein shall constitute an
offer to sell or the solicitation of an offer to buy any
securities.
Contacts: Jordyn TaraziDirector of Investor
RelationsCohBar, Inc.(650)
445-4441Jordyn.tarazi@cohbar.com
CohBar (NASDAQ:CWBR)
Historical Stock Chart
From Aug 2024 to Sep 2024
CohBar (NASDAQ:CWBR)
Historical Stock Chart
From Sep 2023 to Sep 2024